P2X7 and EGCG have been shown to attenuate murine lupus symptoms by inhibiting the activation of NLRP3 inflammasome, thus can be viewed as a promising therapeutic agent in SLE treatment (134–136). The gene discussed is NLRP3; the disease is systemic lupus erythematosus.